Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110106

Peripheral Metabolism of Intact Parathyroid Hormone: ROLE OF LIVER AND KIDNEY AND THE EFFECT OF CHRONIC RENAL FAILURE

K. A. Hruska, A. Korkor, K. Martin, and E. Slatopolsky

The Renal Divisions, Department of Medicine, The Jewish Hospital of St. Louis, Washington University, St. Louis, Missouri 63110

Find articles by Hruska, K. in: PubMed | Google Scholar

The Renal Divisions, Department of Medicine, The Jewish Hospital of St. Louis, Washington University, St. Louis, Missouri 63110

Find articles by Korkor, A. in: PubMed | Google Scholar

The Renal Divisions, Department of Medicine, The Jewish Hospital of St. Louis, Washington University, St. Louis, Missouri 63110

Find articles by Martin, K. in: PubMed | Google Scholar

The Renal Divisions, Department of Medicine, The Jewish Hospital of St. Louis, Washington University, St. Louis, Missouri 63110

Find articles by Slatopolsky, E. in: PubMed | Google Scholar

Published March 1, 1981 - More info

Published in Volume 67, Issue 3 on March 1, 1981
J Clin Invest. 1981;67(3):885–892. https://doi.org/10.1172/JCI110106.
© 1981 The American Society for Clinical Investigation
Published March 1, 1981 - Version history
View PDF
Abstract

The plasma disappearance rate (metabolic clearance rate) of administered intact parathyroid hormone (intact PTH) was analyzed in awake dogs with indwelling hepatic and renal vein catheters. The metabolic clearance rate (MCR) of intact PTH was found to be very rapid, 21.6 ± 3.1 ml/min per kg in 11 normal dogs. The liver accounted for the greatest fraction of the MCR of intact PTH (61 ± 4%) by virtue of an arterial minus venous (a - v) difference across the liver of 45 ± 3%. The renal uptake of intact PTH accounted for 31 ± 3% of the MCR of intact PTH. The renal a - v difference for intact PTH of 29 ± 2% was significantly greater than the filtration fraction indicating renal uptake of intact PTH at sites independent of glomerular filtration. Together, the hepatic and renal clearances of intact PTH accounted for all but a small fraction of the MCR of intact PTH. The MCR of intact PTH, rendered biologically inactive by oxidation, was markedly decreased to 8.8 ± 1 ml/min per kg. The a - v difference of oxidized intact PTH was reduced both in the liver and kidney. These data suggested that the high uptake rates of intact PTH are dependent, at least in part, upon sites recognizing only biologically active PTH.

Chronic renal failure (CRF) decreased the MCR of intact PTH to 11.3 ± 1.3 ml/min per kg (n = 10). Both the hepatic and renal a - v differences of intact PTH were reduced in dogs with CRF. This resulted in reductions in the hepatic and renal clearances of intact PTH. These studies identify the liver as a major extrarenal site of PTH metabolism affected by CRF. They suggest that CRF impairs the function of the major uptake sites involved in intact PTH metabolism.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 885
page 885
icon of scanned page 886
page 886
icon of scanned page 887
page 887
icon of scanned page 888
page 888
icon of scanned page 889
page 889
icon of scanned page 890
page 890
icon of scanned page 891
page 891
icon of scanned page 892
page 892
Version history
  • Version 1 (March 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts